1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

China Rush Over? Korean Firms Step Up To Seize Opportunities

Strong BIO Presence Signals Intent

 
• By Jung Won Shin

Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.

business investment
Will Korean Biophamas Benefit From Derailed China Investment Funds? • Source: Shutterstock

With foreign investment in China cooling off this year because of its stringent COVID-19-related policies and multinationals in the country increasingly uncertain over the general business environment, fund in-flows into neighboring Asian countries are increasing.

While South Korea so far doesn’t appear to be benefiting from this shift, hopes are increasing as pharma and biotech firms, along with relevant industry and government entities, from the northeast Asian country step up globalization and promotion activities, if

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Focus On Asia